Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia-Reference-Cited by-同舟云学术

Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia

Published:2023-11-08 Issue:1 Volume:34 Page:
ISSN:0953-7104
Container-title:Platelets
language:en
Short-container-title:Platelets

Author:

Wang Xiuli¹²,Bi Hui¹,Liu Lin¹,Liu Yuebo¹,Yin Liefen¹,Yao Jin¹,Yu Jingxing¹,Tao Wei¹,Wei Yueping¹,Li Yu¹,Yin Lingmei¹,Mu Hongli¹,Du Yadong³,Zhou Zeping¹

Affiliation:

1. Department of Hematology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China

2. Department of basic teaching and Research, Medical College, Kunming, China

3. Department of Cardiovascular, HanDan Central Hospital, HanDan, China

Funder

Training Plan of Yunnan Medical Leaders

National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/09537104.2023.2271568

Reference25 articles.

1. American Society of Hematology 2019 guidelines for immune thrombocytopenia

2. International consensus report on the investigation and management of primary immune thrombocytopenia

3. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

4. A Randomized Trial of Daily Prednisone versus Pulsed Dexamethasone in Treatment-Naïve Adult Patients with Immune Thrombocytopenia: EIS 2002 Study

5. Autoimmune thrombocytopenic purpura

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of recombinant human thrombopoietin for the treatment of chronic primary immune thrombocytopenia in children and adolescents: A multicentre, randomized, double‐blind, placebo‐controlled phase III trial;British Journal of Haematology;2024-09-12

2. The Immune Thrombocytopenia Treatment Landscape: A Focus on Patient Perspectives and Unmet Clinical Needs;EMJ Hematology;2024-09-11